Integrative multi-omics and experimental validation identify histone acetylation-related genes BCL9L, STX10 and LSM7 as key mediators of PD-1-driven immune evasion and prognosis in non-small cell lung
3 hours ago
- #Non-small cell lung cancer
- #Immune evasion
- #Histone acetylation
- Study explores histone acetylation-related genes (HARGs) impact on PD-1-associated immune microenvironment and prognosis in NSCLC.
- Integrated multi-omics analyses (GSE99531 and TCGA-NSCLC datasets) and experimental validation were used.
- Identified 1419 and 6252 differentially expressed genes in the datasets.
- WGCNA selected a module with 1560 genes strongly correlated with HARG scores.
- 86 causal candidate genes enriched in mitochondrial pathways were identified.
- BCL9L facilitated tumor growth and immune escape; STX10 and LSM7 increased immune infiltration and suppressed tumor progression.
- Anti-PD-1 therapy showed synergistic effects with low-risk genes.
- Key HARGs (BCL9L, STX10, LSM7) critically influence PD-1-associated immune evasion and prognosis.
- Established risk model shows significant prognostic value and immune regulatory function.